Loading
A phase 1/2 trial of Leucovorin, FLOT, Fluorouracil in colorectal cancer, run by Bold Therapeutics, Inc., now recruiting.
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT04421820 by Bold Therapeutics, Inc., with 220 participants planned, started 2020-08-28 and due to reach its primary completion in 2026-06-01. Interventions recorded: BOLD-100 +/- FOLFOX Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI). Conditions listed: Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma. No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Colorectal cancer.
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Colorectal cancer.
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU).
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU).